Lasa Supergenerics Peer Comparison
NSE: LASA | BSE: 540702
₹4.01
As on 16-Nov-2026IST
Market cap
₹22 Cr
Revenue (TTM)
₹6 Cr
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
22 | 44,378 | 27,740 | 17,812 | 13,203 |
Revenue (₹ Cr) |
6 | 10,234 | 2,307 | 2,684 | 710 |
Net Profit (₹ Cr) |
-16.55 | 1,092.67 | 452.55 | 669.74 | 188.64 |
Net Margin (%) |
-253.90 | 10.67 | 19.31 | 24.24 | 25.69 |
RoE (%) |
-29.40 | 21.65 | 23.18 | 19.79 | 20.46 |
Price to Earnings |
-- | 40.58 | 61.30 | 26.60 | 70.10 |
Price-To-Book |
0.47 | 8.30 | 13.67 | 4.91 | 13.79 |
Income Statement (₹ Cr)
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
6.36 | 10,234.10 | 2,307.19 | 2,684.41 | 709.64 |
|
Total Income
|
6.52 | 10,245.27 | 2,343.69 | 2,763.43 | 734.34 |
|
Total Expenditure
|
14.61 | 8,141.47 | 1,602.28 | 1,761.70 | 458.93 |
|
EBITDA
|
-8.26 | 2,092.63 | 704.92 | 922.70 | 250.72 |
|
Depreciation
|
6.01 | 430.12 | 104.34 | 82.27 | 17.12 |
|
EBIT
|
-14.27 | 1,662.51 | 600.57 | 840.44 | 233.59 |
|
Interest
|
0.50 | 151.49 | 28.27 | 5.42 | 8.49 |
|
Other Income
|
0.17 | 11.17 | 36.50 | 79.02 | 24.69 |
|
Exceptional Items
|
-0.94 | -27.85 | 0.00 | -25.66 | 0.00 |
|
Profit before Tax
|
-15.55 | 1,494.35 | 608.80 | 888.39 | 249.79 |
|
Provision for Tax
|
1.01 | 401.68 | 156.25 | 218.65 | 61.16 |
|
Profit after Tax
|
-16.55 | 1,092.67 | 452.55 | 669.74 | 188.64 |
Liabilities (₹ Cr)
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
49.62 | 5,344.04 | 2,029.71 | 3,631.29 | 957.32 |
|
Minority Interest
|
0.00 | 0.82 | 0.00 | 0.00 | -0.30 |
|
Non-Current Liabilities
|
-0.12 | 980.81 | 381.27 | 146.95 | 106.92 |
|
Current Liabilities
|
16.77 | 3,838.93 | 618.58 | 563.70 | 248.88 |
|
Total Liabilities
|
66.57 | 9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 |
Assets (₹ Cr)
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
55.05 | 3,542.74 | 1,471.67 | 1,454.42 | 534.87 |
|
Current Assets
|
10.44 | 6,027.59 | 1,389.85 | 2,864.85 | 723.33 |
|
Total Assets
|
66.57 | 9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 |
|
Total Debt*
|
9.75 | 1,204.08 | 196.61 | 0.00 | 148.29 |
|
Net Current Assets
|
-6.34 | 2,188.66 | 771.28 | 2,301.15 | 474.44 |
|
Contingent Liabilities
|
127.98 | 258.92 | 13.18 | 4.82 | -- |
Cashflow (₹ Cr)
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-7.69 | 943.55 | 346.68 | 565.41 | 69.55 |
|
Cash Flow from Investing Activities
|
0.34 | -1,193.06 | -423.73 | -570.15 | -330.93 |
|
Cash from Financing Activities
|
7.37 | 343.43 | 20.98 | -64.34 | 247.29 |
|
Net Cash Inflow / Outflow
|
0.01 | 93.92 | -56.08 | -69.08 | -14.09 |
Ratios
Profitability Ratios
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-47.09 | 25.25 | 27.50 | 24.61 | 28.50 |
|
ROE (%)
|
-29.40 | 21.65 | 23.18 | 19.79 | 20.46 |
|
ROA (%)
|
-19.73 | 11.17 | 16.27 | 16.78 | 16.29 |
|
EBIT Margin (%)
|
-224.58 | 16.24 | 26.03 | 31.31 | 32.92 |
|
Net Margin (%)
|
-253.90 | 10.67 | 19.31 | 24.24 | 25.69 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-95.17 | 21.12 | 50.46 | 8.19 | 26.57 |
|
EBIT Growth (%)
|
-100.70 | 32.84 | 138.53 | 24.77 | 26.37 |
|
Net Profit Growth (%)
|
50.06 | 33.33 | 88.45 | 26.27 | 24.97 |
|
EPS Growth (%)
|
-164.28 | 38.63 | 131.13 | 29.79 | 8.48 |
|
Book Value Growth (%)
|
-40.72 | 11.36 | 22.95 | 18.43 | 79.97 |
Valuation Ratios
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.35 | 39.82 | 61.30 | 25.80 | 70.10 |
|
Price / Book Value
|
0.47 | 8.30 | 13.67 | 4.91 | 13.79 |
|
Dividend Yield (%)
|
0.00 | 0.15 | 0.16 | 0.35 | 0.13 |
|
EV/EBITDA
|
-3.72 | 21.71 | 39.13 | 18.46 | 52.79 |
|
Market Cap (₹ Cr)
|
28.46 | 30,257.56 | 15,412.11 | 11,956.86 | 6,690.53 |
Solvency Ratios
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.10 | 0.10 | 0.00 | 0.07 |
|
Short term debt to equity ratio
|
0.20 | 0.16 | -- | -- | 0.12 |
|
Current Ratio
|
0.62 | 1.57 | 2.25 | 5.08 | 2.91 |
|
Quick Ratio
|
0.51 | 0.92 | 1.35 | 3.69 | 1.80 |
|
Interest Coverage
|
-30.16 | 10.86 | 22.53 | 165.03 | 30.42 |
Operating Efficiency Ratios
| Lasa Supergenerics | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.65 | 26.69 | 12.76 | 36.81 | 34.68 |
|
Asset Turnover
|
0.08 | 1.05 | 0.83 | 0.67 | 0.61 |
|
Receivable days
|
11.13 | 88.68 | 77.32 | 144.58 | 115.16 |
|
Inventory Days
|
191.01 | 84.11 | 80.83 | 96.67 | 96.15 |
|
Payable days
|
94.45 | 176.65 | 125.94 | 135.45 | 106.08 |
|
Cash Conversion Cycle
|
107.68 | -3.86 | 32.22 | 105.80 | 105.23 |